Introduction
The U.S. healthcare market hit $5.3 trillion in national health expenditures in 2024, growing 7.2% and now accounting for 18.0% of GDP, according to CMS national health expenditure data.
That works out to roughly $15,474 per person. For growth-focused healthcare companies, that scale is hard to ignore.
But bigger isn't simpler. Many companies struggle with how fragmented U.S. healthcare really is: federal agencies, 50 state licensing regimes, private payers, and Medicaid programs that vary by state all pull in different directions.
This article covers the market landscape, entry models, regulatory essentials, a practical step-by-step framework, and the mistakes that trip up even well-funded entrants.
Key Takeaways
- Structured entry planning cuts regulatory, financial, and reputational risk before U.S. spend
- Match your entry model (entity, EOR, partnership, distributor) to capital, timeline, and risk
- Build HIPAA, Stark Law, and Anti-Kickback compliance in from day one
- Cross-border advisory support speeds entry without in-house U.S. healthcare-regulatory hires
Understanding the U.S. Healthcare Market Opportunity
Healthcare spending isn't slowing down. Centers for Medicare & Medicaid Services (CMS) projects national health expenditures will approach $9.0 trillion by 2034, or 20.6% of the economy, per a Health Affairs summary of CMS projections. Digital health funding alone reached $14.2 billion in 2025, a 35% jump from the prior year, according to Rock Health.
That said, entering this market means clearing three sequential hurdles, not one:
- Regulatory approval — FDA clearance, state licensure, or both
- Provider and payer adoption — getting clinicians to use your product and payers to reimburse for it
- Scalability — expanding beyond your first state or region without rebuilding your compliance stack each time
Why Fragmentation Changes the Playbook
Unlike centralized health systems abroad, the U.S. splits authority across federal agencies, state medical boards, and thousands of individual payer contracts. Medicaid, for example, is jointly funded by states and the federal government but administered separately by each state, per Medicaid.gov. A green light in Texas doesn't mean anything in California.
Reimbursement pathways compound this. Medicare runs through federal payment schedules and Medicare Administrative Contractors, Medicaid varies state by state, and commercial payers negotiate coverage individually by provider type, notes PwC's Health Care Guide. There is no single national reimbursement switch to flip.
The 7 Ps as a Positioning Framework
That same fragmentation is why positioning has to come before build decisions. Map your offer against the 7 Ps of healthcare marketing: Product, Price, Place, Promotion, People, Process, and Physical Evidence—the services mix Booms and Bitner extended from McCarthy's original 4 Ps.
Do this early. It clarifies whether you sell to providers, payers, or patients, and how each group judges value differently.
Core Market Entry Models for Healthcare Companies
There's no single "correct" way in. Your choice depends on capital reserves, regulatory exposure, and how fast you need feedback from the U.S. market.
Direct Entity Establishment
Forming an LLC, C-Corp, or subsidiary works best once you have proven demand. Delaware is a common default, but registration there still requires annual franchise-tax filings and does not waive licenses or operational rules in the states where you actually do business.
Key considerations:
- State of incorporation vs. state of operations and licensing
- Franchise tax and annual report obligations
- Registered agent requirements
VJM Global assists with LLC and C-Corporation formation, including EIN acquisition, Registered Agent appointment, and FinCEN beneficial-ownership reporting.
Employer of Record (EOR)
If you need clinical, regulatory, or commercial staff on the ground before full incorporation, an EOR model lets you hire without a legal entity.
VJM Global's EOR service covers compliant contracts, payroll, and statutory contributions across 100+ countries, including the United States—plus onboarding, benefits, and offboarding.
Distributor, Licensing, and Partnership Models
For medtech and pharma companies, distributor and licensing arrangements offer a lower-risk path into provider networks and Group Purchasing Organizations (GPOs).
A 2024 peer-reviewed study found more than 95% of U.S. hospitals use GPO pooling alliances to buy drugs, devices, and supplies. Skip GPO access, and you're locked out of most hospital procurement.
Drug distributors and third-party logistics providers face their own licensing standards under the DSCSA, per the Federal Register.
M&A and Acquisition
Buying an existing U.S. healthcare entity gets you faster access to licenses, payer contracts, and infrastructure already in place. The tradeoff is due diligence complexity: human resources, financials, liabilities, and compliance history all need review before you sign.
VJM Global supports acquirers with due diligence reporting, financial statement review, and offer preparation as part of its M&A advisory work.
Hybrid and Staged Approaches
Many companies pilot through a partnership or EOR arrangement first, then transition to a full entity once demand and reimbursement pathways are validated. This staged approach limits capital exposure while you're still proving product-market fit.
Navigating Healthcare-Specific Regulatory and Compliance Requirements
Healthcare compliance multiplies across three layers (federal, state, and local) in ways that don't apply to most other industries.
FDA and State Licensure
Device manufacturers must register their establishments annually with the FDA and list their devices, including any premarket submission number such as 510(k), De Novo, PMA, PDP, or HDE, per FDA guidance. Drug manufacturers face parallel registration and listing requirements.
State medical licensure runs on a separate track entirely. HHS confirms that provider licensing across state lines involves both federal and state roles — a national FDA approval says nothing about whether your clinicians can legally practice in a given state.
HIPAA: Covered Entities vs. Business Associates
HIPAA obligations depend on your role:
- Covered entities include healthcare providers, health plans, and clearinghouses conducting standard electronic transactions, per HHS
- Business associates create, receive, maintain, or transmit PHI for a covered entity and carry direct liability for specified HIPAA provisions
If you touch patient data at all, you need a written business associate agreement in place before you go live, not after your first data breach.
Fraud and Abuse Statutes
Three statutes matter most:
| Statute | What it prohibits | Key detail |
|---|---|---|
| Anti-Kickback Statute | Remuneration intended to induce referrals for federally payable services | No financial loss or patient harm required to trigger liability |
| Stark Law | Physician referrals to entities with a prohibited financial relationship | Strict liability — intent doesn't matter |
| False Claims Act | Knowingly submitting false claims to Medicare or Medicaid | Reckless disregard is enough; no intent to defraud required |
These aren't niche rules. They apply broadly to referral arrangements, pricing structures, and partnership agreements, per HHS OIG.
Ongoing State Obligations
Beyond initial setup, expect recurring requirements: payroll tax withholding, sales tax nexus registration, annual reports, and state-specific privacy thresholds.
California's CCPA, for instance, applies at an annual gross-revenue threshold of $26,625,000 effective January 2025, or when handling personal data for 100,000+ consumers.
Health-data processors shouldn't assume HIPAA compliance automatically satisfies CCPA. The statutes serve different purposes.
VJM Global manages federal, state, and sales tax compliance across all 50 states—payroll withholding (W-4, W-2, 941, 1099-NEC), corporate filings (1120, 1120-S, 1065), and annual franchise-tax obligations—so teams don't have to stand up that stack in-house.
Step-by-Step Framework to Build a Healthcare Market Entry Strategy
Follow this sequence rather than jumping straight to incorporation:
- Research the reimbursement landscape first. Map payer coverage, competitive positioning, and evidence requirements before committing capital. Skipping this step is the single most common cause of post-launch adoption stalls.
- Choose your entry structure and state. Base this on tax exposure, licensing requirements, and where you'll actually operate, not just where incorporation is cheapest.
- Map every regulatory layer. FDA registration, HIPAA role classification, and state licensure requirements all need separate workstreams.
- Build banking, accounting, and compliance infrastructure from day one. Retrofitting compliance after launch is expensive and slow.
- Launch localized go-to-market efforts. Monitor payer response and adjust your positioning by stakeholder group.
VJM Global's onboarding model follows the same staged path:
- Needs assessment within 1-2 days
- Customized support plan within 2-3 days
- Full operational support targeted within 1-2 weeks
You get a working compliance foundation while state licensing and payer negotiations run in parallel.
Common Mistakes Healthcare Companies Make During U.S. Market Entry
Even well-capitalised entrants stumble on predictable issues:
- Treating federal approval as sufficient. FDA clearance doesn't override state licensure or payer-specific coverage decisions.
- Picking an incorporation state blind. Delaware's legal advantages don't address where you'll actually need to operate or get licensed.
- Delaying payer engagement until after launch. Companies that wait to build evidence and payer relationships often hit adoption walls they can't quickly fix.
- Using one message for every stakeholder. Providers, payers, and patients each need distinct positioning — a pitch that works for a hospital administrator won't land with a patient.
The failure pattern is consistent across digital health: reimbursement risk, not product quality, tends to be the breaking point. Digital therapeutics and virtual-care companies have both faced payer-related setbacks in recent years. Build payer strategy into the entry plan from day one—not after launch.
Frequently Asked Questions
What are the 7 P's of marketing in the healthcare industry?
They are Product, Price, Place, Promotion, People, Process, and Physical Evidence. In healthcare, map each one before launch: clinical offering, payment model, access channel, communications, accountable staff, delivery process, and care-environment proof.
What is the best market entry strategy for a healthcare company entering the U.S.?
Match the path to your capital, regulatory exposure, and timeline. Teams testing demand usually start with EOR or partnerships; those with proven demand move to direct entity formation.
How long does it take to enter the U.S. healthcare market?
There's no single benchmark. Entity formation can take days, but state licensure and payer negotiations usually stretch the full timeline to many months. California physician licensing, for example, advises applying at least six months ahead.
What compliance laws matter most for healthcare market entry?
HIPAA governs how you handle patient data as a covered entity or business associate. Stark Law and the Anti-Kickback Statute govern referrals and financial relationships. FDA registration applies to devices and drugs sold in the U.S.
Can a healthcare company test the U.S. market without forming a legal entity?
Yes. An EOR lets you hire U.S. staff without incorporating. Distributor partnerships can reach provider networks without your own infrastructure. VJM Global offers EOR coverage across 100+ countries, including the U.S.
How does reimbursement affect market entry planning?
The U.S. lacks a single standardized reimbursement pathway. Medicare, Medicaid, and commercial payers each have separate rules, so payer strategy needs to run alongside regulatory approval, not after it.
